Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 839

1.

Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.

Wang D, Raja NU, Trubey CM, Juompan LY, Luo M, Woraratanadharm J, Deitz SB, Yu H, Swain BM, Moore KM, Pratt WD, Hart MK, Dong JY.

J Virol. 2006 Mar;80(6):2738-46.

2.

Chimpanzee adenovirus vaccine protects against Zaire Ebola virus.

Kobinger GP, Feldmann H, Zhi Y, Schumer G, Gao G, Feldmann F, Jones S, Wilson JM.

Virology. 2006 Mar 15;346(2):394-401. Epub 2005 Dec 13.

3.

Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection.

Warfield KL, Olinger G, Deal EM, Swenson DL, Bailey M, Negley DL, Hart MK, Bavari S.

J Immunol. 2005 Jul 15;175(2):1184-91.

4.

Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines.

Dowling W, Thompson E, Badger C, Mellquist JL, Garrison AR, Smith JM, Paragas J, Hogan RJ, Schmaljohn C.

J Virol. 2007 Feb;81(4):1821-37. Epub 2006 Dec 6.

5.

A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults.

Ledgerwood JE, Costner P, Desai N, Holman L, Enama ME, Yamshchikov G, Mulangu S, Hu Z, Andrews CA, Sheets RA, Koup RA, Roederer M, Bailer R, Mascola JR, Pau MG, Sullivan NJ, Goudsmit J, Nabel GJ, Graham BS; VRC 205 Study Team.

Vaccine. 2010 Dec 16;29(2):304-13. doi: 10.1016/j.vaccine.2010.10.037. Epub 2010 Oct 27.

PMID:
21034824
6.

Comparison of the protective efficacy of DNA and baculovirus-derived protein vaccines for EBOLA virus in guinea pigs.

Mellquist-Riemenschneider JL, Garrison AR, Geisbert JB, Saikh KU, Heidebrink KD, Jahrling PB, Ulrich RG, Schmaljohn CS.

Virus Res. 2003 Apr;92(2):187-93.

PMID:
12686428
7.

Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge.

Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, Bavari S.

J Infect Dis. 2007 Nov 15;196 Suppl 2:S430-7.

PMID:
17940980
8.

Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus.

Geisbert TW, Geisbert JB, Leung A, Daddario-DiCaprio KM, Hensley LE, Grolla A, Feldmann H.

J Virol. 2009 Jul;83(14):7296-304. doi: 10.1128/JVI.00561-09. Epub 2009 Apr 22.

10.

Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector.

Pratt WD, Wang D, Nichols DK, Luo M, Woraratanadharm J, Dye JM, Holman DH, Dong JY.

Clin Vaccine Immunol. 2010 Apr;17(4):572-81. doi: 10.1128/CVI.00467-09. Epub 2010 Feb 24.

11.

Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins.

Wilson JA, Bray M, Bakken R, Hart MK.

Virology. 2001 Aug 1;286(2):384-90.

12.

Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy.

Marzi A, Ebihara H, Callison J, Groseth A, Williams KJ, Geisbert TW, Feldmann H.

J Infect Dis. 2011 Nov;204 Suppl 3:S1066-74. doi: 10.1093/infdis/jir348.

13.

Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever.

Jones SM, Stroher U, Fernando L, Qiu X, Alimonti J, Melito P, Bray M, Klenk HD, Feldmann H.

J Infect Dis. 2007 Nov 15;196 Suppl 2:S404-12.

PMID:
17940977
14.

Complex adenovirus-vectored vaccine protects guinea pigs from three strains of Marburg virus challenges.

Wang D, Hevey M, Juompan LY, Trubey CM, Raja NU, Deitz SB, Woraratanadharm J, Luo M, Yu H, Swain BM, Moore KM, Dong JY.

Virology. 2006 Sep 30;353(2):324-32. Epub 2006 Jul 3.

15.

Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice.

Konduru K, Bradfute SB, Jacques J, Manangeeswaran M, Nakamura S, Morshed S, Wood SC, Bavari S, Kaplan GG.

Vaccine. 2011 Apr 5;29(16):2968-77. doi: 10.1016/j.vaccine.2011.01.113. Epub 2011 Feb 15.

16.

VSVΔG/EBOV GP-induced innate protection enhances natural killer cell activity to increase survival in a lethal mouse adapted Ebola virus infection.

Williams KJ, Qiu X, Fernando L, Jones SM, Alimonti JB.

Viral Immunol. 2015 Feb;28(1):51-61. doi: 10.1089/vim.2014.0069.

PMID:
25494457
17.

De novo syntheses of Marburg virus antigens from adenovirus vectors induce potent humoral and cellular immune responses.

Wang D, Schmaljohn AL, Raja NU, Trubey CM, Juompan LY, Luo M, Deitz SB, Yu H, Woraratanadharm J, Holman DH, Moore KM, Swain BM, Pratt WD, Dong JY.

Vaccine. 2006 Apr 5;24(15):2975-86. Epub 2005 Dec 9.

PMID:
16530297
18.

Production of monoclonal antibodies and development of an antigen capture ELISA directed against the envelope glycoprotein GP of Ebola virus.

Lucht A, Grunow R, Otterbein C, Möller P, Feldmann H, Becker S.

Med Microbiol Immunol. 2004 Nov;193(4):181-7. Epub 2003 Oct 31.

PMID:
14593476
19.

Generation of an adenoviral vaccine vector based on simian adenovirus 21.

Roy S, Zhi Y, Kobinger GP, Figueredo J, Calcedo R, Miller JR, Feldmann H, Wilson JM.

J Gen Virol. 2006 Sep;87(Pt 9):2477-85.

PMID:
16894185
20.

Ebola images emerge from the cave.

Diamond MS, Fremont DH.

Cell Host Microbe. 2008 Aug 14;4(2):87-9. doi: 10.1016/j.chom.2008.07.011.

Supplemental Content

Support Center